Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
作者信息
Kim Eun Soo
机构信息
Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
出版信息
Gut Liver. 2021 Mar 15;15(2):149-150. doi: 10.5009/gnl210098.
Abstract
摘要
相似文献
1
Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?英夫利昔单抗与阿达木单抗，哪一种对溃疡性结肠炎更有效？
Gut Liver. 2021 Mar 15;15(2):149-150. doi: 10.5009/gnl210098.
2
Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.戈利木单抗、英夫利昔单抗和阿达木单抗治疗中度至重度活动性溃疡性结肠炎的疗效比较：一项考虑试验设计差异的网状荟萃分析。
Expert Rev Gastroenterol Hepatol. 2015 May;9(5):693-700. doi: 10.1586/17474124.2015.1024657. Epub 2015 Mar 12.
3
Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.英夫利昔单抗、阿达木单抗、戈利木单抗和维多珠单抗用于西班牙中重度溃疡性结肠炎的成本效益分析
Expert Rev Pharmacoecon Outcomes Res. 2018 Jun;18(3):321-329. doi: 10.1080/14737167.2018.1411193. Epub 2017 Dec 2.
4
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.英夫利昔单抗与阿达木单抗治疗溃疡性结肠炎的持久性：16 年单中心经验。
Inflamm Bowel Dis. 2019 Apr 11;25(5):945-954. doi: 10.1093/ibd/izy322.
5
Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.真实世界实践中，一线和二线肿瘤坏死因子抑制剂治疗难治性溃疡性结肠炎患者的疗效。
Indian J Gastroenterol. 2020 Dec;39(6):565-575. doi: 10.1007/s12664-020-01092-1. Epub 2020 Oct 27.
6
Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.英夫利昔单抗既往应答情况及早期血清药物浓度可预测阿达木单抗在溃疡性结肠炎中的疗效。
Aliment Pharmacol Ther. 2014 Dec;40(11-12):1324-32. doi: 10.1111/apt.12968. Epub 2014 Oct 2.
7
Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.阿达木单抗治疗先前接受英夫利昔单抗治疗的溃疡性结肠炎患者的临床结局：一项丹麦单中心队列研究。
Scand J Gastroenterol. 2015 Aug;50(8):1018-24. doi: 10.3109/00365521.2015.1019558. Epub 2015 Apr 10.
8
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.阿达木单抗用于对英夫利昔单抗不耐受或反应丧失的溃疡性结肠炎诱导治疗：一项开放标签研究。
World J Gastroenterol. 2007 Apr 28;13(16):2328-32. doi: 10.3748/wjg.v13.i16.2328.
9
A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.抗 TNF 在儿童和青少年炎症性肠病中的应用综述
Int J Mol Sci. 2019 May 23;20(10):2529. doi: 10.3390/ijms20102529.
10
Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.英夫利昔单抗和阿达木单抗在克罗恩病和溃疡性结肠炎中的疗效比较
Inflamm Bowel Dis. 2016 Apr;22(4):880-5. doi: 10.1097/MIB.0000000000000754.
引用本文的文献
1
Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta-analysis.阿达木单抗治疗重度溃疡性结肠炎的有效性：一项系统评价和荟萃分析。
Health Sci Rep. 2024 Jul 18;7(7):e2210. doi: 10.1002/hsr2.2210. eCollection 2024 Jul.
2
Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study.沙特阿拉伯炎症性肠病（IBD）患者中抗TNF治疗失败的预测因素：一项单中心研究
J Clin Med. 2022 Jul 18;11(14):4157. doi: 10.3390/jcm11144157.
3
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).巴西溃疡性结肠炎的抗 TNF 治疗：巴西炎症性肠病研究组（GEDIIB）的一项全国性回顾性真实世界比较多中心研究。
BMC Gastroenterol. 2022 May 29;22(1):268. doi: 10.1186/s12876-022-02341-7.
本文引用的文献
1
Analysis of colectomy rates for ulcerative colitis in pre- and postbiological eras in Lothian, Scotland.苏格兰洛锡安区生物制剂治疗前后溃疡性结肠炎结肠切除术率分析。
Colorectal Dis. 2021 May;23(5):1175-1183. doi: 10.1111/codi.15491. Epub 2021 Feb 17.
2
Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis.比较英夫利昔单抗与阿达木单抗治疗生物初治溃疡性结肠炎患者的长期结局。
Gut Liver. 2021 Mar 15;15(2):232-242. doi: 10.5009/gnl19433.
3
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.真实世界中炎症性肠病患者的生物制剂使用模式：治疗持久性、转换及同时应用免疫抑制治疗的重要性。
Inflamm Bowel Dis. 2019 Jul 17;25(8):1417-1427. doi: 10.1093/ibd/izz001.
4
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.英夫利昔单抗与阿达木单抗治疗溃疡性结肠炎的持久性：16 年单中心经验。
Inflamm Bowel Dis. 2019 Apr 11;25(5):945-954. doi: 10.1093/ibd/izy322.
5
Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.炎症性肠病患者使用肿瘤坏死因子拮抗剂治疗的时间趋势：基于人群的分析。
Clin Gastroenterol Hepatol. 2017 Jul;15(7):1061-1070.e1. doi: 10.1016/j.cgh.2017.01.035. Epub 2017 Feb 24.
6
Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.英夫利昔单抗与阿达木单抗治疗初治溃疡性结肠炎患者的比较：丹麦全国队列研究
Clin Gastroenterol Hepatol. 2017 Aug;15(8):1218-1225.e7. doi: 10.1016/j.cgh.2016.11.024. Epub 2016 Nov 29.
7
Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.英夫利昔单抗和阿达木单抗治疗溃疡性结肠炎患者的疗效及安全性比较
Aliment Pharmacol Ther. 2016 May;43(9):994-1003. doi: 10.1111/apt.13580. Epub 2016 Mar 15.
8
The impact of biological interventions for ulcerative colitis on health-related quality of life.溃疡性结肠炎生物干预措施对健康相关生活质量的影响。
Cochrane Database Syst Rev. 2015 Sep 22;2015(9):CD008655. doi: 10.1002/14651858.CD008655.pub3.
9
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.阿达木单抗与英夫利昔单抗用于治疗初治抗TNF治疗的成年中重度溃疡性结肠炎患者：间接治疗比较的荟萃分析
J Crohns Colitis. 2014 Jul;8(7):571-81. doi: 10.1016/j.crohns.2014.01.010. Epub 2014 Feb 1.
10
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.阿达木单抗治疗与溃疡性结肠炎患者住院风险降低相关。
Gastroenterology. 2014 Jan;146(1):110-118.e3. doi: 10.1053/j.gastro.2013.09.032. Epub 2013 Sep 22.
Zotero 插件